Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma

✍ Scribed by Tien-Anh Tran; Bhaskar V. S. Kallakury; Robert A. Ambros; Jeffrey S. Ross

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 345 KB
• Volume: 83
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19980715)83:2<276::aid-cncr11>3.0.co;2-q

✦ Synopsis

BACKGROUND.

In vitro studies have shown an antiproliferative effect of tumor necrosis factor (TNF) against various nonsmall cell lung carcinoma (NSCLC) cell lines. However, clinical trials of combined interleukin-2 and TNF-␣ in patients with advanced NSCLC have demonstrated both conflicting and disappointing results.

METHODS.

Immunohistochemical (IHC) staining was performed on formalin fixed, paraffin embedded tissues from 39 bronchogenic adenocarcinomas and 32 squamous cell carcinomas using polyclonal antibodies against TNF-␣, TNF-␤, TNF-R1, and TNF-R2 proteins. IHC positivity was correlated with tumor stage, grade, and patient survival.

RESULTS.

Significant coexpression of TNF-␣, TNF-␤, TNF-R1, and TNF-R2 was observed in NSCLC (significance range, P Ͻ 0.001-0.02). Although immunoreactivity for TNFs remained high in all tumor stages, a loss of TNF-R expression was found in advanced NSCLC (P Ͻ 0.006 for TNF-R1 and P Ͻ 0.003 for TNF-R2), suggesting down-regulation of TNF-Rs in the process of tumor progression. When all stages were considered together, immunoreactivity for TNF-␤(P Ͻ 0.001), TNF-R1, and TNF-R2 (both P Ͻ 0.001) significantly correlated with favorable outcome in univariate analysis. However, when stages were studied separately, an association between immunopositivity for TNF-Rs and favorable prognosis was found only in NSCLC without distant metastasis (P Ͻ 0.04 and P Ͻ 0.005 for TNF-R1 and TNF-R2 in Stage I [according to the American Joint Committee on Cancer staging system] disease, and P Ͻ 0.03 and P Ͻ 0.02 for TNF-R1 and TNF-R2 in Stage III disease). On multivariate analysis, increased expression of TNF-R1 (P Ͻ 0.003) and TNF-R2 (P Ͻ 0.001) as well as tumor stage (P Ͻ 0.001) independently predicted favorable outcome in patients with NSCLC.

CONCLUSIONS.

Although NSCLC exhibits strong coexpression of TNF-␣, TNF-␤, TNF-R1, and TNF-R2, there is a loss/down-regulation of TNF receptors in high stage tumors. TNF-R1 and TNF-R2 positivity independently predicts favorable outcome in NSCLC, particularly in tumors with no clinically distant metastasis. The current study supports a role for TNFs and their receptors in the evolution and